Royalty Pharma (NASDAQ: RPRX) revenue
Royalty Pharma reported revenue of $2,378m for fiscal 2025, 5.1% more than in fiscal 2024 ($2,264m). Since fiscal 2019 its revenue has grown by 31.1%, an average growth of 4.6% a year.
Fiscal 2025 is the highest of the 7 fiscal years on record for Royalty Pharma. The biggest drop was in fiscal 2024, −3.9%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $2,378m | +5.1% | $1,560m | 65.6% |
| 2024 | $2,264m | −3.9% | $1,292m | 57.1% |
| 2023 | $2,355m | +5.2% | $1,492m | 63.4% |
| 2022 | $2,237m | −2.3% | $307.1m | 13.7% |
| 2021 | $2,289m | +7.9% | $1,431m | 62.5% |
| 2020 | $2,122m | +17.0% | $1,595m | 75.2% |
| 2019 | $1,814m | — | $2,623m | 144.6% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Royalty Pharma revenue compared with its sector
By revenue for its latest fiscal year, Royalty Pharma ranks 104th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Royalty Pharma, 5.1%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 102nd | Teladoc Health | $2,530m | −1.5% |
| 103rd | Aveanna Healthcare | $2,433m | 20.2% |
| 104th | Royalty Pharma | $2,378m | 5.1% |
| 105th | HIMS & Hers Health | $2,348m | 59.0% |
| 106th | Exelixis | $2,320m | 7.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Royalty Pharma
- How much revenue did Royalty Pharma make in fiscal 2025?
- Royalty Pharma reported revenue of $2,378m for fiscal 2025, compared with $2,264m in fiscal 2024.
- How much has the revenue of Royalty Pharma grown?
- Between fiscal 2019 and fiscal 2025 it went from $1,814m to $2,378m: 31.1% more, an average growth of 4.6% a year.
- What was the best year for revenue at Royalty Pharma?
- Of its last 7 fiscal years, fiscal 2025, with $2,378m.
- Where does Royalty Pharma rank in its sector by revenue?
- It ranks 104th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Royalty Pharma come from?
- From the annual report (Form 10-K) that Royalty Pharma files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Royalty Pharma files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Royalty Pharma: the Royalty Pharma page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.